Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,054 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Atopic Dermatitis
Interventions: YR001 ointment, Placebo; Drug · Other
Lead sponsor: Hangzhou Yirui Pharmaceutical Technology Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Boynton Beach, Florida • Hollywood, Florida • Weston, Florida + 1 more

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Social support intervention; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atopic Dermatitis, Eczema
Interventions: Tralokinumab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Female only
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2035
U.S. locations: 1
States / cities: La Jolla, California

Conditions: ALLERGIC RHINITIS
Interventions: dust mite extract or placebo; Biological
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Atopic Dermatitis, Eczema
Interventions: Lebrikizumab, Placebo, Topical Corticosteroid (TCS); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more

Conditions: Atopic Dermatitis
Interventions: RPT193, Placebo; Drug · Other
Lead sponsor: RAPT Therapeutics, Inc., a member of the GSK plc group of companies; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 56
States / cities: Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 45 more

Conditions: Atopic Dermatitis
Interventions: Wrist Actigraphy Device, Sleep Headband; Device
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Orlando, Florida • Grayslake, Illinois • Rochester, New York

Conditions: Dermatitis Atopic
Interventions: PF-07038124 and Vehicle, PF-07038124 or vehicle; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Atopic Dermatitis
Interventions: 50 mg S-777469, 200 mg S-777469, 800 mg S-777469, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
Interventions: PBA-0405; Drug
Lead sponsor: Pure Biologics S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Shreveport, Louisiana • Portland, Oregon • Philadelphia, Pennsylvania + 1 more

Conditions: Hereditary Angioedema
Interventions: Ruconest; Biological
Lead sponsor: Bernstein Clinical Research Center; Other
Eligibility: 14 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Birmingham, Alabama • Cincinnati, Ohio

Conditions: Dermatitis, Atopic
Interventions: BBI-5000; Drug
Lead sponsor: Fresh Tracks Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Dermatitis, Atopic
Interventions: GSK1070806, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: North Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 5 more

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus, Vehicle cream; Drug · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid, Stevens-Johnson Syndrome
Interventions: Adalimumab Injection; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis, Psoriasis, Healthy
Interventions: AD subject visit sampling procedures, PS subject visit sampling procedures, Healthy control visit sampling procedures; Other
Lead sponsor: University of Rochester; Other
Eligibility: 13 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hereditary Angioedema (HAE), Angioedema, Bradykinin-mediated Angioedema, C1 Inhibitor Deficiency
Interventions: Deucrictibant XR tablet, Placebo comparator to XR tablet, Deucrictibant 20 mg capsule, Placebo comparator to 20 mg capsule; Drug
Lead sponsor: Institute for Asthma and Allergy; Network
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Wheaton, Maryland

Conditions: Dermatitis Atopic
Interventions: Blood sample, Cheek swab; Other
Lead sponsor: Sanofi; Industry
Eligibility: 0 Years to 11 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 22
States / cities: Birmingham, Alabama • Montgomery, Alabama • Los Angeles, California + 16 more

Conditions: Urticaria, Patch Testing, Dermatitis, Allergy, Contact Sensitization
Interventions: Patch Testing; Procedure
Lead sponsor: Tufts Medical Center; Other
Eligibility: Not listed
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Idiopathic Anaphylaxis, Drug Anaphylaxis, Venom Anaphylaxis, Food Anaphylaxis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 75 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
Interventions: Benralizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Aurora, Colorado • Bethesda, Maryland • Ann Arbor, Michigan + 5 more

Conditions: Chlorhexidine Allergy, Infection, Rash
Interventions: Chlorhexidine gluconate; Drug
Lead sponsor: Celeste Chandonnet; Other
Eligibility: 36 Weeks to 48 Weeks
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Idiopathic Urticaria
Interventions: Omalizumab, Placebo, H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist, Diphenhydramine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 40
States / cities: Scottsdale, Arizona • Mission Viejo, California • Napa, California + 35 more

Conditions: Atopic Dermatitis
Interventions: MEDI3506, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 13
States / cities: Birmingham, Alabama • Santa Monica, California • Jacksonville, Florida + 9 more

Search by objective public record fields.

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

A Culturally Sensitive Social Support Intervention

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

Repeated Nasal Challenge in Skin Prick-puncture Negative and Intradermal Positive Dust Mite Allergic Rhinitis Patients

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wrist Actigraphy Data In Adult Healthy Volunteers And Participants With Atopic Dermatitis (AD)

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis

A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)

A Pharmacokinetic Study to Evaluate BBI-5000 Capsules and Food Effect in Healthy Adult Subjects

Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis

Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema

Subconjunctival Humira for Boston Keratoprosthesis

Skin Microbial Ecology in Atopic Dermatitis

Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)

Evaluating for Contact Allergies in Patients With Chronic Urticaria

Cause of Unexplained Anaphylaxis

Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment

Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age

A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis